Burosumab Therapy in Children with X-Linked HypophosphatemiaThomas O. Carpenter, Anthony A. Portale, Alison Skrinar et al.|New England Journal of Medicine|2018Cited by 479
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A. Imel, Anthony A. Portale, Francis H. Glorieux et al.|The Lancet|2019Cited by 375
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M. Ward, Erik A. Imel, Francis H. Glorieux et al.|The Journal of Clinical Endocrinology & Metabolism|2022Cited by 78
Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemiaWolfgang Högler, Michael P. Whyte, Thomas O. Carpenter et al.|Bone Abstracts|2019Cited by 0
Burosumab Therapy in Children with X-Linked HypophosphatemiaThomas O. Carpenter, Anthony A. Portale, Michael P. Whyte et al.|Digital Commons@Becker (Washington University School of Medicine)|2018Cited by 0